Rebif

Links shared publicly online about this topic

Sanofi’s Lemtrada beats Rebif in new study | InPharm

inpharm.com — “InPharm.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, jobs, events, and service company listings.View full resource at inpharm.com

  • View Related
  • Share

Most Recently Shared on November 14, 2011 at 3:32 pm By:

Pharmafocus Pharmafocus Pharma and Health News

Sanofi’s Lemtrada beats Rebif in new study - http://t.co/gYgviH9Y

3 months ago...

Doctors Alleged to Have Been Paid to Prescribe Multiple Sclerosis Drug Rebif

disabled-world.com — “Allegations a company caused false or fraudulent claims to be submitted to the Medicaid programView full resource at disabled-world.com

  • View Related
  • Share

Most Recently Shared on May 13, 2011 at 10:25 pm By:

disabledworld Disabled World Health Advocate and Health News

Doctors Alleged to Have Been Paid to Prescribe Multiple Sclerosis Drug Rebif http://ff.im/-DiXm7

9 months ago...

Data of focusing on Rebif and Cladribine Tablets to be presented at AAN Annual Meeting

news-medical.net — “EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, today announced that new data from the company's multiple sclerosis portfolio of approved and investigational treatments will be presented at the 62nd Annual Meeting of the American Academy of Neurology taking place April 10 to 17, in Toronto, Canada.View full resource at news-medical.net

  • View Related
  • Share

Most Recently Shared on April 1, 2010 at 12:09 pm By:

Pregnancy_News News-Medical.Net Health News

Pregnancy News: Data of focusing on Rebif and Cladribine Tablets to be presented at AAN Annual Meeting: EMD Serono... http://bit.ly/d8ysYj

2 years ago...

Merck Serono Submits Application For Extension Of Indication For Rebif(R) In Europe

medicalnewstoday.com — “Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today that it has submitted an application to the European Medicines Agency (EMA) to extend the indication of Rebif®, itsView full resource at medicalnewstoday.com

  • View Related
  • Share

Most Recently Shared on June 29, 2011 at 9:05 am By:

mnt_multiplescl MNT Multiple Scl Health News

Merck Serono Submits Application For Extension Of Indication For Rebif(R) In Europe http://mnt.to/3XMv #multiplesclerosis

7 months ago...

Multiple Sclerosis Head-to-Head Study Comparing TYRABRI To Copaxone And Rebif

medicalnewstoday.com — “Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) today announced enrollment of the first patient in a global Phase IIIb, randomized, rater-blinded, active-controlled study designedView full resource at medicalnewstoday.com

  • View Related
  • Share

Most Recently Shared on March 26, 2010 at 4:10 pm By:

mnt_clinical MNT Clinical Trials Health News

Multiple Sclerosis Head-to-Head Study Comparing TYRABRI To Copaxone And Rebif http://mnt.to/3ztw #clinicaltrials

2 years ago...

Is rebif a good medication for MS? Can anyone tell me about it? - Multiple Sclerosis

healthcentral.com — “I just found out I have MS and I am thinking about taking this medication. ...View full resource at healthcentral.com

  • View Related
  • Share

Most Recently Shared on July 15, 2011 at 4:26 pm By:

Health_Tips HealthCentral Tips Health Site

@Kitty_Catrelli Another person had the same question and here is the opinion of a woman taking rebif http://bit.ly/n6Oqp1

7 months ago...

Lemtrada Better At Preventing MS Relapses Than Rebif, But Not At Reducing Disability Risk

medicalnewstoday.com — “Although Lemtrada (alemtuzumab) was found to be more effective in preventing MS relapses than the older drug - Rebif - it did not prevent multiple sclerosis (MS) from becoming disabling in a late-View full resource at medicalnewstoday.com

  • View Related
  • Share

Most Recently Shared on July 11, 2011 at 7:05 pm By:

mnt_multiplescl MNT Multiple Scl Health News

Lemtrada Better At Preventing MS Relapses Than Rebif, But Not At Reducing Disability Risk http://mnt.to/3Y8Z #multiplesclerosis

7 months ago...

Genzyme MS drug shines in head-to-head trial with Rebif | InPharm

inpharm.com — “Genzyme--™s multiple sclerosis candidate Lemtrada has impressed in a new phase II head-to-head trialView full resource at inpharm.com

  • View Related
  • Share

Most Recently Shared on April 18, 2011 at 9:53 am By:

Pharmafocus Pharmafocus Pharma and Health News

Genzyme MS drug shines in head-to-head trial with Rebif http://goo.gl/fb/6yK45

10 months ago...

Merck Serono: REFLEX Study Results Show Treatment With Rebif(R) Delays Conversion To MS In Patients With First Clinical Signs Of The Disease

medicalnewstoday.com — “Merck Serono, a division of Merck KGaA,Darmstadt, Germany, announced that the two-year Phase III REFLEX 1 study met its primary endpoint by demonstrating that Rebif® (interferon beta-1a) signiView full resource at medicalnewstoday.com

  • View Related
  • Share

Most Recently Shared on October 26, 2010 at 3:05 pm By:

mnt_multiplescl MNT Multiple Scl Health News

Merck Serono: REFLEX Study Results Show Treatment With Rebif(R) Delays Conversion To MS In Patients With First Clinica... http://mnt.to/3LJJ

1 year ago...

PharmaLive: Merck Serono: CHMP Gives Positive Opinion for Extended Indication for Rebif to Treat Patients With Early Signs of Multiple Sclerosis

pharmalive.com — “PharmaLive: Merck Serono: CHMP Gives Positive Opinion for Extended Indication for Rebif to Treat Patients With Early Signs of Multiple SclerosisView full resource at pharmalive.com

  • View Related
  • Share

Most Recently Shared on November 18, 2011 at 6:00 pm By:

pharmalive PharmaLive Health News and Pharma

#Merck #Serono: CHMP Gives Positive Opinion for Extended Indication for Rebif to Treat Patients w/Early Signs of #MS: http://t.co/pCuGHH16

3 months ago...

Results from Trial Comparing Teriflunomide and Rebif in Relapsing MS Do Not Meet Primary Goal : National MS Society

nationalmssociety.org — “MS stops people from moving. The National MS Society exists to make sure it doesn't.View full resource at nationalmssociety.org

  • View Related
  • Share

Most Recently Shared on December 20, 2011 at 10:24 pm By:

mssociety National MS Society Support

News! Results from Trial Comparing Teriflunomide and Rebif in Relapsing MS Do Not Meet Primary Goal http://t.co/PZIyCR1e

2 months ago...

MS Trial Alert: Investigators Recruiting for Studies Comparing Ocrelizumab to Rebif® in People with Relapsing MS : National MS Society

nationalmssociety.org — “MS stops people from moving. The National MS Society exists to make sure it doesn't.View full resource at nationalmssociety.org

  • View Related
  • Share

Most Recently Shared on January 17, 2012 at 4:43 pm By:

mssociety National MS Society Support

News! MS Trial Alert: Investigators Recruiting for Studies Comparing Ocrelizumab to Rebif® in People with Relapsing MS http://t.co/xesPKxyl

3 weeks ago...

REFLEX Study Results Show Treatment with Rebif Delays Conversion to MS in Patients with First Clinical Signs of the Disease - Drugs.com MedNews

drugs.com — “Study met its primary endpoint Risk of converting to multiple sclerosis (McDonald criteria) was reduced by half in patients treated with Rebif 44 mcg three timeView full resource at drugs.com

  • View Related
  • Share

Most Recently Shared on October 25, 2010 at 2:12 pm By:

Drugs_Devices Drugs and Devices OW OW Health

REFLEX Study Results Show Treatment with Rebif Delays Conversion to MS in Patients with First Clinical Signs ... http://bit.ly/bzTgZJ #drug

1 year ago...

: Merck Serono: REFLEX Study Results Show Treatment With Rebif(R) Delays Conversion to MS in Patients With First Clinical Signs of the Disease | wallstreet:online

wallstreet-online.de — “GENEVA, October 25, 2010 /PRNewswire/ - Study Met its Primary Endpoint - Risk of Converting to Multiple Sclerosis (McDonald Criteria) Was Reduced by Half in Patients Treated With Rebif(R) 44 mcg Three Times a Week Merck Serono, a division of ...View full resource at wallstreet-online.de

  • View Related
  • Share

Most Recently Shared on October 25, 2010 at 1:38 pm By:

MS_Wisdom2 OrganizedWisdom MS OW Health

Merck Serono: REFLEX Study Results Show Treatment With Rebif(R) Delays Conversion to MS in Patients With First ...... http://bit.ly/bV9uRH

1 year ago...

Drug company Serono settles lawsuit alleging it paid doctors to prescribe - CBS News Investigates - CBS News

cbsnews.com — “Lawsuit alleges drug giant Serono paid doctors to prescribe Rebif Read more by Laura Strickler on CBS News' CBS News Investigates.View full resource at cbsnews.com

  • View Related
  • Share

Most Recently Shared on May 5, 2011 at 10:31 pm By:

georgejelinek George Jelinek Doctor, Emergency Physician, and Physician

Drug company settles for $44m for sending money to doctors to prescribe Rebif in MS http://bit.ly/kflaIc

9 months ago...

The Top 3 resources shared on this topic. More resources.

Key stats and trends about this topic

Related Health Centers

Featuring the top 3 experts for this topic

  • Pharmafocus

    Pharmafocus

    Monthly pharmaceutical, biotech & healthcare news publication for Europe. For pharma & biotech jobs follow @inpharmjobs. Twitter accounts run by @dominic_tyer

    View Profile

  • disabledworld

    Disabled World

    Official Site - Disability News, Community, Videos. Article submissions welcome. Disability and Health RSS feeds for website content.

    View Profile

  • Pregnancy_News

    News-Medical.Net

    Stay up to date with the latest Pregnancy news and research via News-Medical.Net

    View Profile

Advertisement

Share via Email

Share this WisdomCard with others by embedding on your site or blog.

300x260

425x300

560x390